Background of Anti-mouse TIGIT Monoclonal Antibody (Clone: 10A7)
The 10A7 antibody binds to the TIGIT protein (WUCAM, Vstm3 or VSIG9), a novel immune checkpoint receptor with inhibitory function. TIGIT is expressed on T cells and natural killer (NK) cells, and several human cancers, including melanoma, NSCLC, and colorectal cancer. Similar to PD-1, the TIGIT receptor limits antitumor immune response in cancer.
PA007279.m2a: In vivo Grade Recombinant Anti-mouse TIGIT Monoclonal Antibody, Mouse IgG2a Kappa (Clone: 10A7)
Recombinant mouse IgG2a Monoclonal Antibody.
Clone: 10A7.
Isotype: Mouse IgG2a kappa.
Source: The anti-mouse TIGIT monoclonal antibody (clone: 10A7) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 10A7) specifically binds to the mouse TIGIT protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse TIGIT protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Peng Zhang, et al.
Biomark Res. 2024 Jan 16;12(1):7. doi: 10.1186/s40364-023-00543-z.
PMID: 38229100; PMCID: PMC10790541
“As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion.”
(Tags: anti-mouse TIGIT clone 10A7; TIGIT immune checkpoint)
Ahmed Rishiq, et al.
Oncoimmunology. 2023 May 29;12(1):2217735. doi: 10.1080/2162402X.2023.2217735.
PMID: 37261087; PMCID: PMC10228407
“The use of antibodies to block inhibitory receptors, primarily anti-PD1 and CTLA4 (known as checkpoint therapy) revolutionized cancer treatment. However, despite these successes, the majority of cancer patients do not respond to the checkpoint treatment, emphasizing the need for development of additional therapies, which are based on other inhibitory receptors. Human TIGIT is an inhibitory receptor expressed by Natural Killer (NK) and T cells and is mainly known to interact with PVR, Nectin-2, Nectin-3, and Nectin-4.”
(Tags: TIGIT knockout mice; anti-mouse TIGIT antibody 10A7)
Shuguang Zuo, et al.
EBioMedicine. 2021 Feb:64:103240. doi: 10.1016/j.ebiom.2021.103240.
PMID: 33581644; PMCID: PMC7878184
“Oncolytic virotherapy with vaccinia virus (VV) can lead to effective anti-tumor immunity by turning "cold" tumors into "hot" tumors. However, its therapeutic potential is affected by the tumor's local immunosuppressive tumor microenvironment (TME). Therefore, it is necessary to explore the use of immune checkpoint inhibitors to arm oncolytic VVs to enhance their anti-tumor efficacy.”
(Tags: anti-mouse TIGIT mAb; oncolytic vaccinia virus TIGIT)
Waight AB, et al.
Front Immunol. 2020 Oct 7;11:573405. doi: 10.3389/fimmu.2020.573405.
PMID: 33117369; PMCID: PMC7577118
“The molecule "T cell immunoreceptor with immunoglobulin and ITIM domain," or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combination with programmed cell death-1 (PD-1)-directed immune checkpoint blockade, the molecular mechanism behind the observed therapeutic benefits remains poorly understood. Here we demonstrate, using mouse tumor models, that TIGIT blocking antibodies with functional Fc binding potential induce effective anti-tumor response.”
(Tags: anti-TIGIT FcγR engagement; anti-mouse TIGIT clone 10A7)
Yoav Charpak-Amikam, et al.
Nat Commun. 2022 May 5;13(1):2463. doi: 10.1038/s41467-022-30087-z.
PMID: 35513379; PMCID: PMC9072312
“Candida albicans is the most common fungal pathogen and a prevalent cause of deadly bloodstream infections. Better understanding of the immune response against it, and the ways by which it evades immunity, are crucial for developing new therapeutics against it. Natural Killer (NK) cells are innate lymphocytes best known for their role against viruses and tumors.”
(Tags: anti-mouse TIGIT 10A7; TIGIT in fungal infection)